Eikon Therapeutics is a clinical-stage biotechnology company that combines live-cell super-resolution microscopy with drug discovery and development. Its platform visualizes how proteins move inside living cells to inform candidate selection, with a pipeline focused largely on oncology and related indications. Lead programs include agents studied in advanced melanoma and non-small cell lung cancer; commercial revenue remains minimal while assets advance in the clinic.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -105.2 | — |
| Q3 2025 | 0 | — | -71.1 | — |
| Q4 2025 | 0 | — | -79.7 | — |
| Q1 2026 | 0 | — | -83 | — |
| Q2 2026 | 0 | — | -88.4 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Strata Critical Medical, Inc. (SRTA), M Evo Global Acquisition Corp II (MEVO), Clearfield, Inc. (CLFD), Gladstone Land Corporation (LAND), ARS Pharmaceuticals, Inc. (SPRY), Starz Entertainment Corp. (STRZ)